Use of the Perclose ProGlide suture-mediated closure strategy to achieve vascular access-site hemostasis after transfemoral TAVR results in fewer major vascular complications than does deployment of ...

Abbott Park, IL - Abbott Laboratories announced the launch of the next-generation Perclose ® suture-mediated vessel closure system, Perclose ProGlide TM, featuring a polypropylene monofilament suture.

WASHINGTON, DC—For vascular closure after transfemoral TAVI, a strategy that combines suture- and plug-based devices halves the risk of access site-related vascular complications during a patient’s’ ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. LAS VEGAS — In a comparison of two vascular closure ...

A head-to-head comparison of vascular closure devices defied expectations in the CHOICE-CLOSURE trial. For large-bore arterial access site closure after transfemoral transcatheter aortic valve ...

Please provide your email address to receive an email when new articles are posted on . The CHOICE-CLOSURE trial was presented by Mohamed Abdel-Wahab, MD, consultant cardiologist and head of the ...

Abbott declared the 371st consecutive quarterly dividend of 26 cents per share on Sept. 15. The current dividend yield is 2.60%. The company is a long-term dividend payer and has increased its ...